Cytokinetics (CYTK) EVP Callos exercises 15,000 options and sells shares
Rhea-AI Filing Summary
Cytokinetics executive Andrew Callos reported an option exercise and share sale. On 02/05/2026, the EVP and Chief Commercial Officer exercised 15,000 non-qualified stock options at $23.26 per share and received 15,000 shares of common stock.
That same day, he sold 15,000 shares of common stock at $61.93 per share, leaving him with 50,440 shares of common stock held directly and 84,000 stock options remaining. The reported options were originally granted on 03/31/2022 and are scheduled to vest over four years, with an expiration date of 03/31/2031.
Positive
- None.
Negative
- None.
Insider Trade Summary
Exercise and Sale: 15,000 shares ($580K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Callos Andrew
Role
EVP, Chief Commercial Officer
Sold
15,000 shs ($929K)
Approx. gross sale proceeds
$929K
Approx. exercise cost
$349K
Approx. pre-tax spread
$580K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (Right to Buy) | 15,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 15,000 | $23.26 | $349K |
| Sale | Common Stock | 15,000 | $61.93 | $929K |
Holdings After Transaction:
Non-Qualified Stock Option (Right to Buy) — 84,000 shares (Direct);
Common Stock — 50,440 shares (Direct)
Footnotes (1)
- F1. Stock options will vest over 4 years from the date of the grant, with 1/4th of the shares underlying the reporting person's option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the reporting person's option over the subsequent 36 months, subject to the reporting person's continued employment with the Issuer.
FAQ
What insider transaction did Andrew Callos report at Cytokinetics (CYTK)?
Andrew Callos reported exercising 15,000 stock options and selling 15,000 Cytokinetics common shares on 02/05/2026. The exercise was at $23.26 per share and the sale at $61.93 per share, reflecting a same-day option exercise and share sale by the company’s EVP, Chief Commercial Officer.
What type of derivative security did Andrew Callos exercise at Cytokinetics (CYTK)?
He exercised a non-qualified stock option (right to buy) covering 15,000 shares of Cytokinetics common stock. The option has an exercise price of $23.26 per share, was granted on 03/31/2022, and carries an expiration date of 03/31/2031, with vesting over four years.
How do Andrew Callos’s Cytokinetics (CYTK) stock options vest?
The options vest over four years from the 03/31/2022 grant date. One quarter of the shares vest on the first anniversary, and the remaining three quarters vest monthly at 1/48th over the next 36 months, subject to his continued employment with Cytokinetics.
What role does Andrew Callos hold at Cytokinetics (CYTK) in this Form 4?
In the Form 4, Andrew Callos is identified as an officer of Cytokinetics, specifically serving as EVP, Chief Commercial Officer. The filing indicates he is not a director and not a 10% owner, but a Section 16 reporting officer of the company.
AI-generated analysis. How Rhea-AI works. Not financial advice.
